Replimune Group, Inc. (REPL)
Replimune Group, Inc. (REPL) is a Healthcare stock tracked by StreetAlpha. REPL reports earnings on Thu, Nov 5, 2026. The average 12-month price target from 4 analysts is $16.75, with a high of $21.00 and a low of $12.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in REPL, 0% of them bullish and 100% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on REPL in the past 90 days. The average target is $16.75, with a high of $21.00 and a low of $12.00.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | Roth MKM | Initiated | Buy | $17 |
| Aug 26 | JP Morgan | Target raised | Buy | $20 → $21 |
| Aug 7 | JP Morgan | Maintained | Buy | $20 |
| Aug 4 | Leerink Partners | Upgrade | Buy | $2 → $17 |
| Jul 31 | Wedbush | Target raised | Hold | $9 → $12 |
Whale Options Flow
90DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether REPL is in one of them and how their past REPL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered REPL in an article yet. Here's the latest on the wider market.
For informational purposes only. Not financial advice. Options flow and dark pool data are delayed and may be incomplete.